Results 191 to 200 of about 121,769 (336)

14-3-3ζ and aPKC-ι synergistically facilitate epithelial-mesenchymal transition of cholangiocarcinoma via GSK-3β/snail signaling pathway

, 2016
Yan Yang, Yan Liu, Junchuang He, Jianming Wang, Peter Schemmer, Chaoqun Ma, Yawei Qian, Wei Yao, Jian Zhang, Weipeng Qi, Yang Fu, Feng Wei, Tao Yang   +12 more
openalex   +2 more sources

An inactive pool of GSK-3 at the leading edge of growth cones is implicated in Semaphorin 3A signaling [PDF]

, 2002
Britta J. Eickholt, Frank S. Walsh, Patrick Doherty   +2 more
openalex   +1 more source

CDK versus GSK-3 Inhibition [PDF]

Chemistry & Biology, 2003
openaire   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

GSK-3 kinase Mck1 and calcineurin coordinately mediate Hsl1 down-regulation by Ca2+ in budding yeast [PDF]

, 2001
Masaki Mizunuma
openalex   +1 more source

Quantifying the impact of a computer‐aided diagnostic score on the clinical diagnosis of functional seizures

Epilepsia, EarlyView.
Abstract Objective The diagnosis of functional/dissociative seizures (FDS) without ictal video‐electroencephalography is challenging. The Functional/Dissociative Seizures Likelihood Score (FSLS) is a machine learning‐based diagnostic score that aims to help clinicians identify FDS.
Wesley T. Kerr, Katherine N. McFarlane, Corinne H. Allas, Samuel W. Terman, Markus Reuber, Sung Hyun Seo, Payge Barnard, Adriana Y. Koek, Amir H. Karimi, Siddhika S. Sreenivasan, Jena S. Grauer, Di Sun, Meagan Watson, Elissa H. Patterson, James Castellano, Anto I. Bagić, L. Brian Hickman, Kenneth H. Kutschman, Laurence Knowles, Alistair Wardrope, Piyush Ostwal, Bridget K. MacDonald, Melissa Berry, Lomalan Reddy, Najda Robinson‐Mayer, Nicholas J. Beimer, Rachna Reddy, Sarah K. Yaghoubi, Laura A. Kirkpatrick, Danielle R. Carns, Alex J. Israel, Jamie D. Feusner, Zongqi Xia, Yanshan Wang, Laura A. Strom, Page B. Pennell, John M. Stern, Lubomir Hadjiiski, William C. Stacey   +38 more
wiley   +1 more source

GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. [PDF]

Int J Mol Sci, 2023
Huntington KE, Louie AD, Srinivasan PR, Schorl C, Lu S, Silverberg D, Newhouse D, Wu Z, Zhou L, Borden BA, Giles FJ, Dooner M, Carneiro BA, El-Deiry WS.   +13 more
europepmc   +1 more source

Correction: Inhibition of GSK-3 Ameliorates Aβ Pathology in an Adult-Onset Drosophila Model of Alzheimer's Disease

, 2012
Oyinkan Sofola, Fiona Kerr, Iain Rogers, Richard Killick, Hrvoje Augustin, Carina Gandy, Marcus J. Allen, John Hardy, Simon Lovestone, Linda Partridge   +9 more
openalex   +1 more source

Requirement of GSK-3 for PUMA induction upon loss of pro-survival PI3K signaling [PDF]

, 2018
Herta Flor, J. Rapp, Prisca Brauns‐Schubert, Lisa Schlicher, Kerstin Stock, Manuela Wissler, Martina Weiß, Céline Charvet, Christoph Borner, Ulrich Maurer   +9 more
openalex   +1 more source

L‐Relationship between uncertainty and average seizure frequency in clinical trials of antiseizure medications

Epilepsia, EarlyView.
Abstract Objective Antiseizure medications are approved based on clinical trials that demonstrate their efficacy as measured by reductions in seizure frequency (SF). When designing these trials, trialists must select inclusion criteria where SF can be reliably measured to maintain statistical power.
Wesley T. Kerr, Neo Kok, Katherine N. McFarlane, Advith S. Reddy, Lavanya Biju, Jacqueline A. French, Daniel M. Goldenholz   +6 more
wiley   +1 more source